Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

Anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $5.5 billion in 2024. Pfizer expects full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenue.

Is it true that the higher the dividend yield, the riskier the dividend? Not always. Some companies with exceptionally high ...

Tuesday was a fairly eventful news day for U.S. pharmaceutical sector company Pfizer (NYSE: PFE). It reported third-quarter ...

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer (PFE) continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 ...

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer still expects to achieve full-year 2024 operational revenue growth of 9 to 11 percent. The company ...

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...